Cyberonics reneged on its "Lifetime Reimbursement Guarantee". Click on the image to learn how you can help...

Monday, February 7, 2011

Treatment of asthmatic bronchoconstriction by percutaneous low voltage vagal nerve stimulation: case report.

The Internet Journal of Asthma, Allergy and Immunology 2009 :     Volume 7 Number 2

Treatment of asthmatic bronchoconstriction by percutaneous low voltage vagal nerve stimulation: case report.

  Pedro Sepulveda MD Director, Alamo Clinical Research Center, San Antionio, TX                                                              
  Gorav Bohill MD Emergency Department Director, Christua Santa Rosa Hospital, San Antonio, TX                                                            
 Thomas J. Hoffmann BS ElectroCore LLC, Morris Plains, NJ                                                            
Citation:          P. Sepulveda,        G. Bohill &       T. Hoffmann : Treatment of asthmatic bronchoconstriction by percutaneous low voltage vagal nerve stimulation: case report.. The Internet Journal of Asthma, Allergy and Immunology. 2009 Volume 7 Number 2

Keywords: Asthma | vagus nerve stimulation | bronchoconstriction | bronchodilation | dyspnea | FEV1 | spirometry


Background: A 34 year old Hispanic male patient presented himself in the emergency room with recurring severe asthma that was unresponsive to b-adrenergic and steroid therapy. Spirometry demonstrated significant airflow obstruction. Objective: We sought to test the ability of low voltage vagus nerve stimulation to induce bronchodilation and improve airflow.Method: A percutaneous electrode was inserted into the patient’s neck and positioned to lie in the vicinity of  the carotid sheath. Following placement,  stimulation was administered and the signal amplitude slowly increased until muscle twitching or discomfort was reported by the patient then reduced to a comfortable level.  Results: Within minutes of stimulation, the patient reported reduced dyspnea that was confirmed by spirometry fifteen minutes later (FEV1 increased from 2.70 L to 3.18 L).   The FEV1 remained elevated during the 180min treatment (3.29 ± 0.04 L) and at 30min post stimulation (3.36 L).  The FEV1 then decreased to 2.84 L 60min after stimulation ended. Conclusion: This finding indicates that low voltage vagus nerve stimulation could be a useful critical care treatment to alleviate smooth muscle bronchoconstriction and offer a new therapeutic approach to the treatment of acute asthma. 

Financial Support

This study was conducted as part of an FDA IDE and sponsored by ElectroCore LLC, Morris Plains, NJ.


VNS: Vagal nerve stimulation
FEV1 - forced expiratory volume in 1 second


Asthma is a common chronic lung disease characterized by pulmonary inflammation and bronchoconstriction resulting in dyspnea. When severe, asthma can be life threatening and require emergency medical treatment and hospitalization. In a recent American Lung Association report, there were 1.8 million emergency department visits and 3,816 deaths per year attributable to asthma  1 . Medical treatment may include supplemental oxygen to treat the hypoxemia, and pharmacologic agents such as -agonists to relieve the bronchoconstriction, anticholinergics to treat the vagal reflex component of bronchoconstriction, and corticosteroids to treat inflammation. Here we report on the first patient to be treated with a new pulsed electrical vagal nerve stimulation device that may open a new therapeutic approach for the temporary treatment of acute asthma. This study was conducted as part of an FDA IDE, and was completed under IRB supervision.

Case Presentation

A 34 year-old Hispanic male patient with a four year history of severe asthma and a former smoker was admitted to the emergency department with an acute asthma attack. He reported self treatment with albuterol without success. Upon admission, the patient was alert and calm but demonstrated bilateral wheezing, elevated blood pressure (BP) (163/92 mmHg) related to chronic hypertension, acute bronchitis, and mild throat hyperemia. All other vital signs were normal. The patient was administered conventional pharmacologic therapy over a 9 hour period without benefit. Treatment included albuterol (2.5mg), prednisone (60mg PO), and zithromax (500mg PO). At five hours, spirometry assessment of the lung function revealed a Forced Expiratory Volume in 1 second (FEV1) of 2.68 L or 69% of predicted  2 . After eight hours, the patient was provided information on this study, was consented, and entered a 90 minute observation period. During this time, the patient continued to receive pharmacologic therapy (2.5mg albuterol) and began supplemental oxygen (2 L/min). The patient then underwent placement of a percutaneous, bipolar electrode to stimulate the right vagus nerve (figure 1).
The patient was prepped and draped and, using anatomical landmarks and ultrasound guidance, the electrode lead was inserted to a position parallel to the right vagus nerve in the vicinity of the carotid sheath. The patient remained fully conscious and responsive during the procedure and received only local anesthesia at the insertion site. The electrode insertion was uneventful and a sub-threshold test confirmed the device was functioning. Spirometry was repeated and FEV1 remained impaired at 2.70 L. Stimulation strength was gradually increased until the patient felt a mild muscle twitch at 7.5 volts (25Hz, 200s pulse width signal) then reduced to 7 volts. This setting achieved therapeutic levels without discomfort and the patient was able to repeat the FEV1 test without difficulty. At the 15min test point, FEV1 had improved to 3.18 L and stabilized during 180 minutes of testing (3.29 ± 0.04 L, 85% predicted). Benefit remained during the first thirty minutes after terminating treatment (3.38 L) then decreased. At 60 minutes post stimulation, FEV1 was only modestly elevated above pre-stimulation levels (2.84 L, 73% predicted) (figure 2). The patient remained under observation overnight to monitor the concomitant hypertension and then discharged. At the 1-week follow-up visit, the exam showed complete healing of the insertion site, and the patient reported no after effects from the treatment.
Figure 1. Patient with a percutaneous VNS electrode
Figure 1. Patient with a percutaneous VNS electrode
Figure 2. The effect of VNS on FEV1
Figure 2. The effect of VNS on FEV1


Here, we report on the first use of vagus nerve stimulation (VNS) in a human asthma patient to treat bronchoconstriction. Although a form of VNS has been in clinical use for over ten years  3  for the non-pharmacologic treatment of seizure disorders and depression, until now, VNS has not been applicable for the treatment for asthma. Indeed in one report on a patient with intractable seizures, VNS Therapy™ was associated with dyspnea although this was easily remedied after reprogramming the stimulation signal 4 . A further limitation of VNS Therapy™ is that the procedure requires direct visualization and manipulation of the vagus nerve in order to attach an electrode array. In the treatment report here, invasive surgery was not required. Instead a minimally invasive, percutaneous approach was used to position an electrode in close proximity to the nerve. This was a relatively simple and rapid procedure that was performed in the emergency department and completed in approximately 10 minutes without evidence of bleeding or scarring.

The neural pathways of the parasympathetic nervous system are the primary regulators of pulmonary smooth muscle tone. Postganglionic parasympathetic nerves mediate both cholinergic contractions and inhibitory nonadrenergic noncholinergic (iNANC) relaxations. It is the close balance between these two that ultimately determines airway caliber. Electrophysiological studies suggest that these relaxation and contraction responses are through anatomical and physiological distinct vagus nerve pathways  5 .

In animal studies, relatively high levels of direct vagal nerve stimulation have been used to induce bronchoconstriction  6,7 . Recently, our group has found that similarly applied low voltage stimulation could be used to reduce histamine induced bronchoconstriction in two animal models  8 . This has led to the development of a new percutaneous proximity neurostimulator for stimulating the cervical vagus nerve that was used in this study.

In animal models, VNS is frequently used to investigate the neural pathways and receptors involved in controlling the airways and their association with asthma. Electrical stimulation of the vagus nerve can result in the release of acetylcholine from its pulmonary endings to activate muscarinic acetylcholine receptors on airway smooth muscle cells and induce bronchoconstriction. In contrast, we have demonstrated previously in animal models  8  and now in a human patient that VNS can be used to reduce bronchoconstriction associated with asthma. Although the mechanism has not been fully established, iNANC nerves constitute a likely neural pathway since they can be activated by electrical stimulation and are known to mediate relaxation in human airways  9 .

In this patient, normal pharmacological therapy with β2-agonist inhalation was ineffective. It is possible that the airway limitations and reduced inhalation volume created inefficiencies in airflow dynamics. Therapeutic aerosol delivery involves impaction, sedimentation, and diffusion  10 . During an acute asthma episode, the air flow changes from what is largely laminar under normal circumstances to a pattern with increasing velocities and turbulence. This makes delivery of the pharmacological inhalation agents to the distal lungs difficult, both by reducing transport and by depleting the concentration through impact and absorption in the upper respiratory tract. The application of this new VNS treatment bypasses airflow limitations to bring immediate bronchodilation. The resulting improvement in airflow dynamics provided by VNS can then facilitate the delivery of standard inhalation therapies to achieve prolonged remission of asthma symptoms.


The specific VNS signal applied in this study suggests that stimulation can safely reduce bronchoconstriction. This offers an exciting new opportunity to provide a non-pharmacological and non-airflow dependent treatment modality to emergency department practice for acute asthma as well as a potential new rescue treatment in critical care settings.

Correspondence to

Dr. Pedro Sepulveda
Phone:             210-223-3010
Fax:                 210-222-2942


1. American Lung Association, Epidemiology & Statistics Unit.  Trends in asthma morbidity and mortality.  November 2007.  Available at  Accessed February 12, 2009.(s)
2. Crapo RO, Jensen RL, Lockey JE, Aldrich V, Elliott CG. Normal spirometric values in healthy Hispanic Americans.  Chest. 1990; 98:1435-9.(s)
3. Cyberonics, Inc. Corporate profile. Houston, Texas U.S.A. 77058, Available at:  Accessed January 19, 2008.(s)
4. Bijwadia, JS, Hoch RC, Dexter DD.  Identification and treatment of bronchoconstriction induced by a vagus nerve stimulator employed for management of seizure disorder. Chest 2005; 127:401-402(s)
5. Mazzone SB, Canning BJ. Evidence for differential reflex regulation of cholinergic and noncholinergic parasympathetic nerves innervating the airways. Am J Respir Crit Care Med 2002; 165:1076-1083(s)
6. Jooste E, Zhang Y, Emala CW. Neuromuscular blocking agents' differential bronchoconstrictive potential in Guinea pig airways. Anesthesiology. 2007; 106:763-72.(s)
7. Blaber LC, Fryer AD, Maclagan J. Neuronal muscarinic receptors attenuate vagally-induced contraction of feline bronchial smooth muscle. Br J Pharmacol. 1985; 86:723-8.(s)
8. Hoffmann TJ, Mendez S, Staats P, Emala CW, Guo P. Inhibition of Histamine-Induced Bronchoconstriction in Guinea Pig and Swine by Pulsed Electrical Vagus Nerve Stimulation.  Neuromodulation. in press(s)
9. Maarsingh H, Leusink J, Bos TS, Zaagsma J, Meurs H. Arginase strongly impairs neuronal nitric oxide-mediated airway smooth muscle relaxation in allergic asthma. Respir Res. 2006; 7:6 .  Accessed February 2, 2009.(s)
10. Newhouse MT, Dolovich M. Aerosol therapy of reversible airflow obstruction. Concepts and clinical applications. Chest. 1987; 91: 58S-64S.(s)

This article was last modified on Fri, 23 Oct 09 21:23:45 -0500
This page was generated on Mon, 07 Feb 11 20:23:34 -0600, and may be cached.

Friday, February 4, 2011

Magnetic device making waves in depression therapy

New Kit for VNS

Recently Cyberonics
(NasdaqGS: CYBX
- News), a leading
neuromodulation company, has received approval from the US Food and Drug
Administration (FDA) for AspireHC (High Capacity), a new and improved generator
to be used in vagus nerve stimulation (VNS) therapy.

Cyberonics expects the AspireHC generator, represents the fifth
generation of VNS Therapy. It has longer battery life, more user-friendly
features and improved electronics that proves more beneficial to VNS patients
as well the physicians. This approval will also pave the way for introduction
of new products in future like the AspireSR seizure response system, whose the
European clinical trial is expected by the first half of 2011. Cyberonics plans
to begin the limited launch of AspireHC generator in the first quarter of
fiscal 2011 (ending April 29).

Cyberonics’ VNS system is a non drug, surgically implanted medical
device that stimulates the vagus nerve by sending electrically pulsed signals.
It is specially used for treatment-resistant depression when all other
anti-depressant treatments fail.

Cyberonics’ VNS therapy system is the first implantable medical
device to receive FDA approval for the treatment of epilepsy. The device has
the potential to treat other neurological disorders, such as depression,
Alzheimer’s disease, anxiety, bulimia, fibromyalgia, obesity, obsessive-compulsive
disorder, multiple sclerosis and traumatic brain injury. The device is widely
accepted amongst neurosurgeons, as reflected by the sales of the company. Till
now more than 60,000 patients worldwide have been implanted with the VNS
therapy system for epilepsy and many more have used it for depression.

Cyberonics reported revenues of $47.5 million during the second
quarter of fiscal 2011, 17% higher than $40.7 million in the year-ago period.
Sales related to epilepsy units increased 14% in the US and 6% in the
international market.

Cyberonicsenjoys a strong position in the neuromodulation market.
We are encouraged by its improvement in the international business. With the
presence of players such as Medtronic
(NYSE: MDT - News) and St. Jude Medical
(NYSE: STJ - News), the company faces stiff
competition. We are also concerned about the reimbursement related issues faced
currently by the company.